Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer therapy. This study aimed to develop novel risk classifiers to predict the risk of immune-related adverse events (irAEs) and the probability of clinical benefits. Patients with cancer who received ICIs from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ni, Jiang, Aimin, Shang, Xiao, Zhao, Fumei, Wang, Ruoxuan, Fu, Xiao, Ruan, Zhiping, Liang, Xuan, Tian, Tao, Yao, Yu, Li, Chunli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473032/
https://www.ncbi.nlm.nih.gov/pubmed/37335173
http://dx.doi.org/10.1097/CJI.0000000000000478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473032/
https://www.ncbi.nlm.nih.gov/pubmed/37335173
http://dx.doi.org/10.1097/CJI.0000000000000478

Ejemplares similares